EpiVario Signs Option Agreement with the University of Pennsylvania for a New Epigenetic Marker for Alzheimer's Disease

3 min read
Company raises additional capital to close Seed Funding of $717K.
EpiVario We are thrilled to continue our collaboration with the University of Pennsylvania, as well as to close this round of funding to help us continue and expand our research... - Thomas Kim, CEO of EpiVario

EpiVario, Inc., a preclinical stage drug discovery and development company, today announced that it has entered into an option agreement with the University of Pennsylvania for an epigenetic marker that could potentially be targeted to develop drug treatments for early-stage Alzheimer's disease therapy.

According to the World Health Organization (WHO), there are nearly 50 million individuals living with dementia worldwide. Of those cases, 60 to 70 percent are thought to be attributed to Alzheimer's disease, which is now among the top 10 causes of death worldwide.

"Given the incidence of Alzheimer's disease around the world and its devastating effects on individuals, there has never been a greater need for early intervention," said Shelley Berger, Ph.D., the Daniel S. Och University Professor in the Perelman School of Medicine at the University of Pennsylvania, one of EpiVario's co-founders, and the senior scientist on this research. "With this new epigenetic marker, there is an opportunity to develop novel therapeutics that can inhibit the epigenetic regulators that contribute to the disease."

Under the terms of the agreement, EpiVario holds the first option to negotiate an exclusive license agreement…
Read full article